Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: TBL 12 Clear all

Conditions: Alzheimer's Disease
Interventions: Memantine, Placebo; Drug
Lead sponsor: Florida Atlantic University; Other
Eligibility: 60 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Physical Activity in Children
Interventions: UNICEF kid power program immediately, UNICEF kid power program for waitlist control, ActiGraph Accelerometer; Behavioral · Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 8 Years to 11 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: INS018_055, Placebo; Drug
Lead sponsor: InSilico Medicine Hong Kong Limited; Industry
Eligibility: 40 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 12
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 8 more

Conditions: Multiple Organ Failure
Interventions: CoQ10, Placebo; Dietary Supplement
Lead sponsor: American Burn Association; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: HIV
Interventions: dolutegravir, Triumeq, Truvada; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Nocturia
Interventions: FE 201836, Desmopressin, Placebo oral solution, Placebo ODT; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 43
States / cities: Birmingham, Alabama • Mobile, Alabama • Lincoln, California + 35 more

Conditions: Alzheimer Disease, Healthy Volunteers
Interventions: TAK-071, Donepezil, TAK-071 Placebo, Donepezil Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 179 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Chronic Fatigue Syndrome (CFS), Myalgic Encephalomyelitis (ME)
Interventions: Methyl-P plus Nutrient Formula, Methyl-P plus Nutrient matched placebos; Drug
Lead sponsor: K-PAX Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Stanford, California • Fort Lauderdale, Florida • New York, New York + 1 more

Conditions: Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Interventions: Ampreloxetine, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 30 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 26
States / cities: Scottsdale, Arizona • Fountain Valley, California • La Jolla, California + 21 more

Conditions: Osteosarcoma Recurrent, Ewing's Tumor Recurrent
Interventions: DFMO; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: Up to 39 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: HIV Infection, Vaginal Atrophy, Menopause, Menopause Related Conditions, Aging, Premature Aging, Atrophic Vaginitis, Dysbiosis, Vaginitis
Interventions: Estradiol Vaginal Insert; Drug
Lead sponsor: Kerry Murphy; Other
Eligibility: 45 Years to 70 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Rheumatoid Arthritis
Interventions: Upadacitinib, Pneumococcal 13-valent conjugate vaccine (PCV-13); Drug · Biological
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 52
States / cities: Huntsville, Alabama • Phoenix, Arizona • Hemet, California + 44 more

Conditions: Healthy Volunteers
Interventions: GSBR-1290 (Capsule/Tablet), GSBR-1290, Placebo, Placebo (Capsule/Tablet); Drug
Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Miami, Florida • Baltimore, Maryland

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL/VOX; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 17
States / cities: Los Angeles, California • Palo Alto, California • Rialto, California + 12 more

Conditions: Opioid-Related Disorders
Interventions: Naltrexone for extended-release injectable suspension, Oral naltrexone; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Pelvic Organ Prolapse
Interventions: Solifenacin, Placebo, Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex; Drug · Device
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Endometrial Cancer, Recurrent Endometrial Cancer, TP53
Interventions: Abemaciclib, Letrozole, Pembrolizumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 8
States / cities: Aurora, Colorado • Boston, Massachusetts • Foxborough, Massachusetts + 3 more

Conditions: Hepatitis C
Interventions: Daclatasvir, Asunaprevir, BMS-791325, Ribavirin, Placebo matching Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 26
States / cities: La Jolla, California • San Diego, California • San Francisco, California + 22 more

Conditions: Tobacco Use Disorder, Opioid-use Disorder
Interventions: Long-Term Varenicline, Short-Term Varenicline, Directly Observed Therapy, Self Administered Therapy; Drug · Behavioral
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Asthma
Interventions: 10 mg tablet of montelukast (Singulair); Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 7 Years to 35 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Parkinson's Disease
Interventions: Niacin, Niacinamide, Placebo; Dietary Supplement · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 35 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Interaction Drug Food
Interventions: Cinnamon (2 g), Nicotine gum (2.5 mg), Letrozole (2.5 mg); Dietary Supplement · Drug
Lead sponsor: Washington State University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Cancer Survivors
Interventions: Remote Assessment of Physical Function with Direct Observation, Remote Assessment of Physical Function; Other
Lead sponsor: University of New Mexico; Other
Eligibility: 60 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Cystic Fibrosis
Interventions: ergocalciferol (vitamin D2), Sperti Del Sol Lamp, Vitamin D3; Drug · Device
Lead sponsor: Atlanta VA Medical Center; Federal
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease

Web-based Physical Activity Intervention for Children

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

Efficacy of Coenzyme Q10 Supplementation on Multi-Organ Dysfunction in Severely Burned Patients

Dolutegravir in Reservoirs

A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

The Synergy Trial: Methylphenidate Plus a CFS-Specific Nutrient Formula as a Treatment for Chronic Fatigue Syndrome

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma

Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial

An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis

A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants

Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings

Clinical Trial of Solifenacin Versus Placebo Plus Pessary for Women With Vaginal Prolapse

ALPINE: Maintenance Letrozole/Abemaciclib

UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis

A Trial of Directly Observed and Long-term Varenicline

Genotype Stratified Pharmacokinetic Study of Montelukast

Low Dose Niacin (Vitamin B3) for Parkinson's Disease

Evaluating the Pharmacokinetics and Drug Interaction Potential of the Botanical Dietary Supplement Cinnamon

Remote Assessment of Physical Function

Improving Vitamin D Status In Cystic Fibrosis